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In this study, we report the crystal structure of the cytochrome P450
CYP260A1 (PDB 5LIV) from the myxobacterium Sorangium cellulosum So
ce56. In addition, we investigated the hydroxylation of 11-deoxycorticoster-
one by CYP260A1 by reconstituting the enzyme with the surrogate redox
partners adrenodoxin and adrenodoxin reductase. The major product of this
steroid conversion was identified as 1a-hydroxy-11-deoxycorticosterone, a
novel D4 C-21 steroidal derivative. Furthermore, we docked the substrate into
the crystal structure and replaced Ser326, the residue responsible for sub-
strate orientation, with asparagine and observed that the mutant S326N
displayed higher activity and selectivity for the formation of 1a-hydroxy-11-
deoxycorticosterone compared to the wild-type CYP260A1. Thus, our find-
ings highlight the usefulness of the obtained crystal structure of CYP260A1
in identifying biotechnologically more efficient reactions.
Keywords: crystal structure of CYP260A1; mineralocorticoid; P450;
S326N; steroid hydroxylation
Cytochromes P450 (P450s) are heme monoxygenases
or the mixed-function oxidases, which can catalyze a
number of reactions involved in the metabolism of
steroids, fatty acids, drugs, xenobiotics, terpenes, and
terpenoids [1–7], as well as the late-stage functionaliza-
tion of several bioactive secondary metabolites [8].
P450s are available in eukaryotes and prokaryotes
mainly as multi-component systems and require one or
two redox partners for electron transfer from the
cofactor NAD(P)H to the heme-iron [9].
The attempt of studying P450s to employ them as a
biocatalyst for the generation of industrially and phar-
maceutically valuable novel biomolecules is considered
as a center of attraction for several investigations.
Among them, the investigation of steroid hydroxylat-
ing P450s is of great interest, because of the
pharmaceutical values of the steroidal derivatives.
Although 14 human P450s (CYP1B1, CYP7A1,
CYP7B1, CYP8B1, CYP11A1, CYPB1, CYP11B2,
CYP17A1, CYP19A1, CYP21A2, CYP27A1,
CYP39A1, CYP46A1, and CYP51A1) are able to per-
form physiologically relevant steroid hydroxylation
[10], the membrane integrated feature and the low
expression level of these P450s hindered their applica-
tion as biocatalysts. In this regard, bacterial P450s
could be the best alternatives. However, there are only
few bacterial P450s which can convert steroidal mole-
cules including CYP106A1 [11], CYP106A2 [12,13],
CYP125 [14,15], CYP142 [16], CYP154C5 [17], and
CYP260 [18–20].
The myxobacterium S. cellulosum So ce56, the pro-
ducer of the novel cytotoxic compound chevasazole
Abbreviation
AdR, adrenodoxin reductase, Adx, adrenodoxin.
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[21] and of catecholate-type siderophores, myxochelins
[22], contains 21 P450s [23], 8 ferredoxin, and 2 ferre-
doxin reductases [24]. Among them, CYP260A1 is one
of the novel P450s, which we have recently shown to
perform a selective 1a-hydroxylation of C-19 steroids
[20]. In addition, the oxidation of sesquiterpenes [25]
and conversion of drugs [26] by CYP260A1 was also
demonstrated. Although its autologous redox partners
Fdx2/FdRB and Fdx8/FdRB were identified as effi-
cient for sesquiterpene oxidation [24], the bovine redox
partners adrenodoxin (Adx4–108) and adrenodoxin
reductase (AdR) were shown to be efficient surrogate
redox partners [23], and they were employed for the
establishment of an Escherichia coli-based whole-cell
system [27].
In this study, the crystal structure of CYP260A1
was solved for the first time, and the conversion of a
model D4 C21 steroid, 11-deoxycorticosterone (DOC)
was investigated. The major product of the DOC con-
version by CYP260A1 was purified and identified as
1a-hydroxylated product by 1D- and 2D-NMR analy-
sis, which turned out to be a novel derivative of DOC.
In order to investigate the structure–function relation-
ship, DOC was docked into the crystal structure. The
residue Ser326, a residue responsible for positioning
the substrate in the active site of CYP260A1, was
replaced by asparagine and the conversion of DOC
was compared with that of the wild-type.
Materials and methods
Molecular cloning, expression, and purification of
CYP260A1, S326N, and other proteins
The heterologous expression and purification of CYP260A1
was performed as described elsewhere [20]. In order to gen-
erate the S326N mutant, the CYP260A1 construct was
mutated by site-directed mutagenesis using primers 50-
aggggatgcgctggtgcccgagcAActttggcgtgctgcgaatggt-30 (forward)
and 50- accattcgcagcacgccaaagTTgctcgggcaccagcgcatcccct-30
(reverse) and a mutagenesis kit (Stratagene Ltd, Cambridge,
UK). The correct sequence of the expression construct was
confirmed by automated sequencing (MWG-biotech AG,
Ebersberg, Germany). The mutated protein was expressed
and purified as the wild-type CYP260A1. The mammalian
adrenodoxin reductase, AdR, and truncated adrenodoxin,
Adx4–108, were expressed and purified as described [28,29].
Crystallization and structure refinement
CYP260A1 with the highest purity observed by SDS/
PAGE and UV-visible spectroscopy analysis was concen-
trated to 25 mgmL1 with a Spin_X UF 50K column
(Corning) in 100 mM potassium phosphate buffer (pH 7.4).
The screening of the crystallization conditions was per-
formed with 96-well sitting drop vapor diffusion plates of
Crystal Screen HT Kit (Hampton Research) at 18 °C using
the automated crystallization facility at the Department of
Structural Biology [30] in the presence and absence of
DOC (200 lM).
Nonoptimized crystals were obtained with enzyme prein-
cubated with DOC (200 lM) in 100 lM MES monohydrate,
pH 6.5, containing 1.6 M magnesium sulfate heptahydrate.
Different pH values and drop volume ratios were used to
optimize the crystallization conditions in 24-well plates using
the hanging drop method considering preliminary buffer
selection. Reddish crystals used for X-ray diffraction experi-
ments were collected from the same condition at pH 6.8
using equal protein/buffer ratios in the droplets. Crystals
with hexagonal shape appeared over a period of 2 weeks and
had dimensions of 230 lM in a diameter. For cryo-protec-
tion, crystals were passed through the reservoir solution con-
taining 42% PEG8000 before flash-cooled in liquid nitrogen.
X-ray diffraction data were collected at Beamline ID14-4
from the European Synchrotron Radiation Facility in
Grenoble, France, available through the Frankfurt-Hom-
burg Blocked Allocation Group (BAG MX-1303). To define
an optimal strategy for data collection, EDNA framework
[31] and its automated indexing, cell refinement and strategy
calculation were used during data acquisition. All datasets
were indexed, integrated, and scaled using Mosflm [32] and
Scala [33] from the CCP4 program suite [34]. The CYP260A1
structure was solved by molecular replacement using the
chain A of the CYP260B1 (PDB 5HIW) [18] with the pro-
gram Molrep [35,36]. Model building was performed with
the program COOT [37] and refinement using REFMAC5
[38]. All structural figures were prepared using PyMOL (The
PyMOL Molecular Graphics System, Version 1.3 Schr€odin-
ger, LLC, New York, NY, USA).
UV–visible absorption spectroscopy
UV–visible spectra for CYP260A1 were measured at room
temperature on a double-beam spectrophotometer (UV-
2101PC, Shimadzu, Japan). The protein dissolved in 10 mM
potassium phosphate buffer, pH 7.4, was used for the spec-
tral measurements of the oxidized and reduced form. The
protein was reduced with few grains of sodium dithionite.
The active form of CYP260A1 was confirmed by CO-dif-
ference spectroscopy using De(450–490) = 91 mM
1cm1
according to the method described elsewhere [39].
In vitro enzyme activity assay
The conversion of DOC by the CYP260A1 was carried out
with the heterologous electron partners. A protein ratio of
CYP260A1 : Adx : AdR of 1 : 10 : 3 was used. The
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in vitro reconstitution assay was performed in a final vol-
ume of 250 lL in 20 mM potassium phosphate buffer, pH
7.4. The reaction was started by adding NADPH (1 mM)
and incubated for 20 min at 30 °C. The reaction was
stopped by the addition of 500 lL chloroform and
extracted as described [20].
Whole-cell biotransformation using resting cells
The whole-cell biotransformation assay was performed in
E. coli C43(DE3) cells. The cells were transformed with
two plasmids, one for the CYP260A1 and the other one for
the redox partners, AdR and Adx4–108, as described [27].
The seed culture was grown overnight at 37 °C in LB
media containing streptomycin (50 lgmL1) and ampicillin
(100 lgmL1). The main culture was inoculated with the
overnight culture (1 : 100 dilution) in Terrific broth med-
ium. The expression was induced by adding 1 mM isopropyl
b-D-1-thiogalactopyranoside and 0.5 mM 5-aminolevulinic
acid at an optical density of 1. After 24 or 48 h of expres-
sion at 28 °C, the cells were harvested by centrifugation for
20 min at 4500 g. The cell pellet was resuspended and
washed in 20 mM potassium phosphate buffer, pH 7.4, con-
taining 2% glycerol followed by a centrifugation step. The
2.4 g cell mass was suspended in 100 mL buffer containing
2% glycerol. The substrate (200 lM) and EDTA (20 mM)
were added and the cells were incubated for 24 h at 30 °C.
The reaction was stopped by adding the same volume of
chloroform and extracted as described [20].
HPLC and LC-MS analysis for DOC conversion by
CYP260A1
The sample was mixed vigorously and the organic phase
was extracted twice with chloroform. The pooled samples
were dried in speed-vac and analyzed by HPLC as
described [20]. Briefly, the steroids were resuspended in
50% acetonitrile and separated on a Jasco reversed phase
HPLC system (Tokyo, Japan) composed of an auto sam-
pler AS-2050 plus, pump PU-2080, gradient mixer LG-
2080-02, and an UV-detector UV-2075. A reversed phase
column (Nucleodur R100-5 C18ec, particle size 3 lm,
length 125 mm, and internal diameter 4 mm, Macherey-
Nagel) was used to separate DOC and its products. The
separation of the substrate was done by a gradient elution
of acetonitrile 10–100% for 15 min and was monitored at
240 nm. The column temperature was kept constant at
40 °C with a peltier oven. The sample volume of 20 lL
was injected into the HPLC for the analysis. The peaks
were identified by using the ChromPass software
(V.1.7.403.1, Jasco, Gross-Umstadt, Germany). Pure ster-
oids (> 99%) were used as standards to identify the reten-
tion time (tR) of the peaks on HPLC. For the LC-MS
measurement, the HPLC from WaterAlliance2695 con-
taining diode-array-detector 990 coupled with ESI-MS
(Bruker, Germany) was used. For ionization, atmospheric
pressure chemical ionization was measured in positive mode
using the same column and gradient as mentioned earlier.
NMR characterization of the CYP260A1 product
The fractions of the purified product were pooled and
dried in a rotary evaporator. The residue was dissolved in
CDCl3 for NMR analysis. NMR data were recorded with
a Bruker DRX (Rheinstetten, Germany) 500 NMR spec-
trometer at 300 K at NMR spectroscopy facility (Institut
f€ur Pharmazeutische Biologie, Universit€at des Saarlandes).
The chemical shifts were relative to CHCl3 at d 7.24 (
1H
NMR) or CDCl3 at d 77.00 (
13C NMR) using the stan-
dard d notation in parts per million (p.p.m.). The 1D
NMR (1H and 13C NMR, DEPT135) and the 2D NMR
spectra (gs-HH-COSY, gs-NOESY, gs-HSQCED, and gs-
HMBC) was recorded using BRUKER pulse program
library.
Docking of substrates into the crystal structure
of CYP260B1
The automated docking program AUTODOCK (version
4.20) [40,41] was applied for docking of DOC locally into
the substrate-free crystal structure of CYP260A1 that we
have solved in this study. The Windows version 1.5.6 of
Autodock Tools was used to compute Kollman charges for
the enzyme CYP260A1 and Gasteiger–Marsili charges for
the steroidal ligands [42]. A partial charge of +0.400e was
assigned manually to the heme-iron, which corresponds to
Fe(II) that was compensated by adjusting the partial
charges of the ligating nitrogen atoms to 0.348e. Flexible
bonds of the ligands were assigned automatically and veri-
fied by manual inspection. The local docking was per-
formed using a cubic grid box (54 9 54 9 54 points with a
grid spacing of 0.375 A) was centered 5 A above the heme-
iron. For each of the ligands, 100 docking runs were car-
ried out applying the Lamarckian genetic algorithm using
default parameter settings.
Results and Discussion
Overall crystal structure of CYP260A1
The crystal structure of CYP260A1 in the space group
P3221 was solved at 2.67 A resolution. As a model,
the crystal structure of CYP260B1 from S. cellulosum
So ce56 (PDB entry 5HIW) with a sequence identity
of 47% was used [18] for the molecular replacement.
The crystal structure of CYP260A1 consisted of four
molecules in the asymmetric unit (Fig. 1A). The first
50 amino acid residues were unresolved because of the
absence of the electron density in this region and seem
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to be very flexible. The amino acids were traced at the
N terminus from Met51 in chain B and C, Ser48 in
chain A and Asp52 in chain D. At the C terminus, the
electron density until His446 in chains A, B, and D,
and His445 in chain C was determined. In addition,
gaps with lacking electron density were observed at the
residue Gly168 in chain A, Pro214-Met215 and
Arg241-Asp245 in chain B, and Pro194-Glu196 in
chain D. Each of the molecules contains a heme group
and water molecules as described in Table 1.
Three chains (A, C, and D) of CYP260A1 show a
closed conformation with glycerol molecules bound in
the active sites. In these chains, the loop between the
F-helix and the G-helix covers the access channel
which leads from the enzyme surface to the heme-cen-
ter (Fig. 1B). In contrast, only the active site of chain
B contains water molecules and differs in the location
of the F and G helices compared to the other three
chains (Fig. 1C). In addition, the F-G loop is flexible
in chain B with no visible electron density and seems
to be in open conformation. Such ligand free open and
closed conformations have also been reported for P450
PikC from Streptomyces venezuelae [43]. Furthermore,
it has been observed that the substrate-free P450epoK
Fig. 1. Crystal structure of CYP260A1. A. The four molecules, chain A (cyan), chain B (orange), chain C (blue), and chain D (gray) were
found in the asymmetric unit of the substrate-free crystal structure of CYP260A1. B. The superimposed structure of the open conformation
of chain B (orange) and the close conformation of chain C (blue) is shown. C. The 12a-helices (A-helix to L-helix) and 8b-strands (b1–b8) in
the chain C of CYP260A1 is shown. D. The active site residues of CYP260A1 with the two coordinated water molecules (W613 and W665)
(light blue spheres) are shown.
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crystallized in a nearly closed conformation [44] com-
pared with the open form observed for CYP102A1
(P450BM-3) [45] and CYP109B1 from Bacillus subtilis
[46]. The observed open and close conformations are
stabilized by the respective crystal packing forces. The
interconversion between these conformations is essen-
tial for substrate access to the active site, catalysis, and
the subsequent release of the product.
CYP260A1 displays the classic P450 topology con-
sisting of 12 a-helices (A-helix – L-helix) and 8
b-strands (Fig. 1B). The central I-helix runs through
the whole molecule with a length of approximately
48 A. The F-helix and G-helix are projected outside
forming the access channel. The heme-iron is bound to
the proximal cysteine, Cys390 (2.2 A distance), and
embedded between the distal I-helix and the proximal
Table 1. Data collection and refinement statistics of the crystal of CY260A1.
PDB entry 5LIV
Beamline ID14-4 (ESRF, Grenoble)
Space group P3221 (154)
Unit cell dimensions
a, b, c [A] 234.56, 234.56, 96.43
a/b/c [°] 90/90/120
Wavelength [A] 0.9393
Resolution of data [A]\a 69.93–2.67 (2.72–2.67)
No. of observationsa 47 3782 (21277)
No. of unique reflectionsa 86 158 (4459)









CC (1/2)a 0.992 (0.764)





No. of molecules in the asymmetric unit 4
Residues included in the model (total no. of protein atoms) 1570 (12183)
Water molecules (belonging to chain A/B/C/D) 337 (78/66/117/76)
Ligands Protoporphyrin IX containing Fe,
dimethyl sulfoxide (DMSO), glycerol,
2-(N-morpholino)-ethanesulfonic
acid (MES), sulfate ion
Overall B factor [A2] 44.0
B Factor for protein chains [A2]
Overall 40.97
A/B/C/D 47.14/51.88/34.94/44.14
B Factors for ligands [A2]
Waters 33.63





rmsd for bond lengths [A] 0.017
rmsd for bond angles [°] 1.920



































eCalculation of Rfree was performed analogous to Rcryst excluding 5% of randomly chosen reflexes.
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L-helix. The A- and B-rings of the heme in CYP260A1
show an interaction with the hydrophobic polypeptide
chain with nonpolar residues from the D-, I-, and
L-helices, which is a very common topologic feature of
most of the P450s. The heme propionate groups are
tightly bound to side chains of His131, Arg135,
Arg331, and His388, in which the C-ring propionate
forms a salt bridge with the side chain of Arg331
(Fig. 1D) and the D-ring propionate interacts with the
N atoms from the side chains of Arg135, His131, and
His388.
The active site of CYP260A1 consists of the residues
Phe114, Leu119, Ala124, Leu209, Leu212, Val213,
Leu274, Ser275, Leu278, Gly279, Glu282, Thr283,
Ser326, Phe327, Leu330, and Val432 (Fig. 1D). In the
substrate-free crystal structure of CYP260A1, the con-
served Thr283 is placed toward the heme-center and
forms an acid–alcohol pair with Glu282. This acid–al-
cohol pair was considered to be involved in the P450
catalysis [47–50]. The residue Glu282 interacts via a
hydrogen bond with Arg206. In addition, there is a
water molecule coordinated only in the chain B
(Fig. 1D). The detailed structural characteristics are
listed in Table 1. The structure factors as well as the
final coordinates have been deposited in the Protein
Data Bank under ID 5LIV.
In vitro and in vivo conversion of DOC by
CYP260A1
Although we have recently shown that CYP260A1 per-
formed the 1a-hydroxylation of C-19 steroids [20], C-
21 steroids have never been tested. In this study,
DOC, a mineralocorticoid, was used for the conver-
sion of D4 C-21 steroids and the characterization of its
major product.
The LC-MS measurement of the in vitro conversion
of DOC ([M+Z]+ = 331.2) showed two main products
(peak 4; ~ 26% and peak 6; ~ 11%) at a retention
time (tR) of 5.28 min and 7.13 min with [M+H]
+ of
347.2 and 329.2 indicating a monohydroxylated pro-
duct (Dm/z of +16), and the formation of either an
additional double bond, an epoxide, or a keto group
(Dm/z of 2), respectively. In addition, four side-pro-
ducts corresponding to the peaks 1 (~ 3% with
[M+Z]+ = 363.2), 2 (~ 2% with [M+Z]+ = 345.2), 3
(~ 4% with [M+Z]+ = 347.2), and 5 (~ 2% with
[M+Z]+ = 347.2) at tR of 4.13, 4.41, 5.07, and
6.36 min, respectively, were also obtained during the
in vitro reaction. The product peak 1 (Dm/z of +32),
both the peaks 3 and 6 (each having Dm/z of +16) and
peak 2 (Dm/z of +14) indicated double hydroxylation,
single hydroxylation, and an addition of a hydroxy-
group along with the formation of either a double
bond, an epoxide or a keto group, respectively
(Fig. 2A). Steady-state kinetic investigations of the
DOC conversion showed a Km value of 25  4 lM
and a catalytic maximum rate of 1.74  0.07 min1
(Fig. 2C).
As we were interested to characterize the major pro-
duct peak 4, CYP260A1-dependent E. coli-based
whole-cell bioconversion of DOC was performed. The
in vivo conversion of DOC using CYP260A1 and a
coexpression of Adx and AdR showed an identical
product pattern that has been observed during the
in vitro reaction (Fig. 2B). Our optimized E. coli-based
Fig. 2. LC-MS chromatogram of the in vitro (A) and an E. coli based whole-cell conversion (B) of DOC by CYP260A1. The activity was
reconstituted with the heterologous redox partners Adx and AdR. The ratio of CYP260A1 : Adx : AdR was 1 : 10 : 3. The numbers
indicated in the chromatogram represent the product peaks for the conversion of DOC. The major product corresponding to peak 4 was
identified as 1a-hydroxylated-11-DOC. C. Kinetic study of DOC conversion. The error bar in the figures represents the standard deviation of
3–5 independent measurements.
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whole-cell system was able to produce a high enough
yield to purify the major product peak 4
(tR = 5.28 min, Dm/z of +16) and the product was
characterized by 1D- and 2D-NMR. The product was
identified as 1a-hydroxy-11-deoxycorticosterone
(Table 2).
The production of 1a-hydroxylated steroids by
chemical means is very challenging. Although a nine-
step synthesis of 1a-hydroxytestosterone from
dihydrotestosterone [51] as well as the synthesis of 1a-
hydroxycorticosterone from corticosterone 21-acetate
[52] or a somewhat shorter route from 17b-
hydroxyandrosta-1,4-diene-3-one [53] have been
reported, the yields of the 1a-hydroxylated products
were either very low or a mixture of 1a- and 2a-epoxy
derivatives was obtained. In addition, the detection of
1b-hydroxytestosterone either by human liver micro-
somes or by the recombinant CYP3A4 enzyme has
been described. However, the yield is very low and
associated with a mixture of other steroidal products.
As the modification at position C-1 of the steroidal A-
ring is a prerequisite to derive some synthetic anabolic
steroids like mesterolone and methenolone [54,55], the
explicit production of the 1a-hydroxy derivative of
DOC in this study and in our recent study of produc-
ing the 1a-hydroxylated products from D4 C-19 ster-
oids (testosterone, androstenedione, 11-oxo-
androstendione) [20] highlights the biotechnological
significance of CYP260A1.
Docking study
As CYP260A1 was able to produce peak 4 as the
major product from the conversion of DOC, we
were interested to investigate the structure–function
relationship for such selectivity. For this, the
substrate-free crystal structure of CYP260A1 that has
been solved in this study was used for docking experi-
ments.
The docking of DOC into the substrate-free crystal
structure of CYP260A1 showed four different poses
(Table S1). The frequency of the docking cluster for
the pose I is very negligible (only 1%) despite having
the lowest energy (11.29 kcalmol1) compared to
the poses II (~ 38%), III (~ 21%), and IV (~ 40%)
with the mean binding energy of 10.68, 10.80, and
10.81 kcalmol1, respectively.
In the pose II, the energetically most feasible con-
formation shows the D-ring of the substrate oriented
toward the Ser275 residue (Fig. 3A). In this pose, the
3-keto group at the A-ring of DOC showed a hydro-
gen bond with Ser326 (~ 2.092 A), in addition to a
hydrogen bond between the C21 carbonyl group and
Ala124 (~ 2.199 A). As a result, the substrate was
held above the heme-plane giving accesses to the
hydroxylation of D- and C-rings, in which the dis-
tance from Fe to C14 of the substrate is the shortest
(3.736 A) followed by Fe-C7 (3.764) (Table S1,
Fig. 3A). Likewise, the pose IV also showed a similar
orientation, in which the D-ring of the DOC is closer
to the heme-plane (Fig. 3C, Table S1) and the active
site is comprised of Phe114, Ser275, Leu278, Gly279,
Leu330, Phe327, and Val329 without any hydrogen
bond interactions.








Carbon dC dH (J in Hz)
1 72.04 4.08 dd (3.5/3)
2 42.86 2.75 dd (17/3)
2.55 dd (17/3.5/1)
3 196.41 –
4 123.48 5.79 dd (1/1)
5 166.60 –
6 32.84 2.39 m
2.36 m
7 31.00 1.83 m
1.08 dddd (13/13/11.5/5.5)
8 35.20 1.56 ddd (11.5/11/3.5)
9 44.70 1.70 m
10 43.17 –
11 20.32 1.66 dddd (11.5/11.5/3.5/3.5)
1.43 m
12 38.21 1.93 m
1.42 m
13 44.67 –
14 56.08 1.24 m
15 24.55 1.78 m
1.34 m
16 22.95 2.22 m
1.77 m
17 59.09 2.46 dd (9/9)
18 13.44 0.69 s (3H)
19 18.54 1.18 s (3H)
20 210.12 –
21 69.42 4.20 dd (19/4.5)
4.14 dd (19/4)
21-OH – 3.21 dd (4.5/4)
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However, docking pose III showed a horizontally
flipped orientation of the substrate compared to the
poses II and IV, in which the 3-keto group of the
A-ring of the DOC faced toward the Ser275 residue
and displays two hydrogen bonds between C21 car-
bonyl group and Tyr426 (2.131 A) as well as Val432
(1.792 A) (Fig. 3B). In this pose, the active site con-
sists of Leu209, Ser275, Gly279, Leu278, Thr283,
Ser326, Phe327, Gly328, Val432, and Tyr426. This ori-
entation of the substrate provides the most feasible
hydroxylation position at C-1 (~ 4.239 A), which,
indeed, is the major product observed throughout the
in vitro and in vivo conversion of DOC as the product
peak 4 (Dm/z of +16), identified as 1a-hydroxy-11-
deoxycorticosterone.
Site-directed mutagenesis of CYP260A1
As in our docking experiment, pose II (Fig. 3A)
showed a hydrogen bond between the 3-keto group of
DOC at the A-ring with Ser326 leading to less accessi-
bility for the hydroxylation at the position C1 com-
pared with poses III and IV (Table S1), we were
interested to study the effect of Ser326 onto the cat-
alytic activity and selectivity of DOC conversion.
Therefore, in order to disrupt the existing hydrogen
bond between the 3-keto group of DOC and S326, we
aimed to create a mutant giving more access of DOC
to the heme-plane of CYP260A1. Asparagine (Asp/N)
which has a carboxamide side chain instead of the
hydroxyl group was chosen to replace the Ser326 resi-
due so that the substrate could fit into the active site
Fig. 3. Docking conformations of DOC into the crystal structure of
CYP260A1. The docking poses II (A), III (B), and IV (C) are shown.
The default program of Autodock version 4.2 was used. The ligand
steroid is shown as green stick, surrounded by a molecular
surface. The surface is colored with atomic colors in regions that
contact the receptor, and gray in regions that are not in contact.
The carbon surface is shown in red. The hydrogen bonds (in a
wireframed-sphere) are shown in green dotted lines. The most
possible hydroxylating C-atoms from the heme-center (blue dashed
line) to the DOC are shown. The steroidal rings are represented by
A to D, and the most feasible hydroxylating positions identified by
P450s are numbered.
Fig. 4. Comparison of the steady-state in vitro conversion of DOC by
wild-type CYP260A1 (blank bar) and S326N (gray bar). The products
obtained upon the conversion of DOC by the P450s are shown as the
product peaks P1-P6. The error bar in the figures represents the
standard deviation of five independent measurements. The activity
was reconstituted with the heterologous redox partners Adx and AdR.
The ratio of CYP260A1 : Adx : AdR was 1 : 20 : 3. The major product
corresponding to peak 4 was identified as 1a-hydroxylated-DOC.
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and could maintain the polarity of the residue. In fact,
the mutant S326N showed a twofold higher conversion
(~ 95% vs ~ 48%) and ~ 2-fold better selectivity for
peak 4, the 1a-hydroxy-DOC product, compared with
the wild-type CYP260A1 (~ 76% vs 26%) (Fig. 4).
In addition, the observed docking conformation also
showed the possibility to accommodate the substrate
or the preformed product(s) either having the A- or
D-ring closure toward the heme-plane, suggesting the
possibility of multiple hydroxylations. As S326N
showed higher activity and selectivity for the product
4 (1a-hydroxylated product) compared with the wild-
type CYP260A1, it is hypothesized that the absence of
the residue Ser326 might have oriented the substrate
as observed in docking pose II (Fig. 3B) resulting in
the more pronounced production of the product peak
4, the 1a-hydroxy-11-DOC (Fig. 4).
In conclusion, the crystal structure of CYP260A1
has been solved for the first time and the structure–
function relationship for the conversion of DOC was
studied. As the 1a-hydroxylated product of steroids
has a potential pharmaceutical importance, the
increase of the selectivity of 1a-hydroxylation by the
variant S326N created by engineering the active site of
CYP260A1 proves the way to use CYP260A1 also for
the derivatization of other steroids and steroidal drugs.
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